BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37036472)

  • 21. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
    Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
    J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of human epidermal growth factor receptor 2 status and systemic therapy in breast cancer with brain metastases treated with radiotherapy.
    Tsuruoka S; Kataoka M; Uwatsu K; Makita K; Tsuruoka K; Takata N; Ishikawa H; Hamamoto Y; Mochizuki T; Kido T
    Asia Pac J Clin Oncol; 2023 Jun; 19(3):347-354. PubMed ID: 36281655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
    Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
    Cappuzzo F; Toschi L; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Cancellieri A; Magrini E; Bemis L; Franklin WA; Crino L; Bunn PA; Hirsch FR; Varella-Garcia M
    Br J Cancer; 2005 Dec; 93(12):1334-40. PubMed ID: 16288303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.
    Sperduto PW; Kased N; Roberge D; Chao ST; Shanley R; Luo X; Sneed PK; Suh J; Weil RJ; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
    J Neurooncol; 2013 May; 112(3):467-72. PubMed ID: 23462853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
    Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS
    Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal management of brain metastases from breast cancer. Issues and considerations.
    Bartsch R; Berghoff AS; Preusser M
    CNS Drugs; 2013 Feb; 27(2):121-34. PubMed ID: 23239265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.
    Cacho-Díaz B; Cuapantécatl LD; Garcilazo-Reyes YJ; Cabrera-Miranda L; Hernandez-Martinez JM; Arrieta O
    Oncology; 2022; 100(10):542-554. PubMed ID: 35988535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subtype switching in breast cancer brain metastases: a multicenter analysis.
    Hulsbergen AFC; Claes A; Kavouridis VK; Ansaripour A; Nogarede C; Hughes ME; Smith TR; Brastianos PK; Verhoeff JJC; Lin NU; Broekman MLD
    Neuro Oncol; 2020 Aug; 22(8):1173-1181. PubMed ID: 31970416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases.
    Luo D; Ye X; Hu Z; Peng K; Song Y; Yin X; Zhu G; Ji Q; Peng Y
    Tumour Biol; 2014 Mar; 35(3):2437-44. PubMed ID: 24197981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
    Umelo I; Noeparast A; Chen G; Renard M; Geers C; Vansteenkiste J; Giron P; De Wever O; Teugels E; De Grève J
    Oncotarget; 2016 Jan; 7(3):3068-83. PubMed ID: 26689995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.
    Aceto N; Duss S; MacDonald G; Meyer DS; Roloff TC; Hynes NE; Bentires-Alj M
    Breast Cancer Res; 2012 Oct; 14(5):R131. PubMed ID: 23062209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
    Yu X; Sheng J; Pan G; Fan Y
    Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China.
    Li Y; Li Q; Mo H; Guan X; Lin S; Wang Z; Chen Y; Zhang Y; Zhang D; Chen S; Cai R; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Ma F; Xu B
    Breast; 2021 Feb; 55():30-36. PubMed ID: 33310633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The G Protein-Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3.
    Moody TW; Lee L; Jensen RT
    J Mol Neurosci; 2021 Aug; 71(8):1589-1597. PubMed ID: 32964398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.
    Duchnowska R; Sperinde J; Chenna A; Huang W; Weidler JM; Winslow J; Haddad M; Paquet A; Lie Y; Trojanowski T; Mandat T; Kowalczyk A; Czartoryska-Arłukowicz B; Radecka B; Jarosz B; Staszkiewicz R; Kalinka-Warzocha E; Chudzik M; Biernat W; Jassem J
    Neuro Oncol; 2015 Sep; 17(9):1241-9. PubMed ID: 25681308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases.
    Contreras-Zárate MJ; Day NL; Ormond DR; Borges VF; Tobet S; Gril B; Steeg PS; Cittelly DM
    Oncogene; 2019 Jun; 38(24):4685-4699. PubMed ID: 30796353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.